Arrowhead Pharmaceuticals (ARWR) Research & Development (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Research & Development data on file, last reported at $173.3 million in Q1 2026.

• Quarterly Research & Development rose 30.17% year-over-year to $173.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $687.5 million (up 23.13% YoY) and the FY2025 annual result came in at $607.2 million, up 20.02% from the prior year.
• Research & Development retreated to $173.3 million in Q1 2026, from $177.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $177.2 million in Q4 2025 to a low of $72.2 million in Q2 2022.
• A 5-year average of $120.5 million and a median of $116.5 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development soared 70.0% — and 2023, when it retreated 1.45%.
• Tracing ARWR's Research & Development over 5 years: stood at $83.7 million in 2022, then jumped by 39.19% to $116.5 million in 2023, then increased by 17.61% to $137.0 million in 2024, then grew by 29.34% to $177.2 million in 2025, then fell by 2.23% to $173.3 million in 2026.
• The last three Research & Development figures came in at $173.3 million (Q1 2026), $177.2 million (Q4 2025), and $174.7 million (Q3 2025), per Business Quant data.